Celcuity reports combo regimen with gedatolisib doubles progression‑free survival odds in late‑stage breast cancer
read at Endpoints ↗Positive readoutPositive
Celcuity announced at ASCO 2026 that its experimental drug gedatolisib, used in a combination regimen, showed a significant improvement in a late‑stage breast cancer trial.
The data revealed that patients receiving the combination were twice as likely to remain free of disease progression or death compared with the control group.
Following the positive readout, Celcuity said it will pursue another FDA filing to seek broader approval for the regimen.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “#ASCO26: Celcuity plans another FDA filing after positive breast cancer readout”
read at Endpoints ↗90 words · retrieved Jun 2
comments(0)
5-min edit window · permanent after that